These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35965315)

  • 1. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
    Chen ML; Wu RM
    J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
    Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
    PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
    Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
    Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease.
    Tagliaferro P; Kareva T; Oo TF; Yarygina O; Kholodilov N; Burke RE
    Neurobiol Dis; 2015 Oct; 82():359-371. PubMed ID: 26192625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-motor and motor features in LRRK2 transgenic mice.
    Bichler Z; Lim HC; Zeng L; Tan EK
    PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT
    Lim J; Bang Y; Choi JH; Han A; Kwon MS; Liu KH; Choi HJ
    J Neurosci; 2018 Feb; 38(7):1611-1621. PubMed ID: 29305532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2
    Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL
    Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
    Hatano T; Funayama M; Kubo SI; Mata IF; Oji Y; Mori A; Zabetian CP; Waldherr SM; Yoshino H; Oyama G; Shimo Y; Fujimoto KI; Oshima H; Kunii Y; Yabe H; Mizuno Y; Hattori N
    Neurobiol Aging; 2014 Nov; 35(11):2656.e17-2656.e23. PubMed ID: 24973808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
    Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
    Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
    Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
    Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of mitochondrial Ca
    Chang EE; Liu H; Choi ZY; Malki Y; Zhang SX; Pang SY; Kung MH; Ramsden DB; Ho SL; Ho PW
    Cell Commun Signal; 2024 Oct; 22(1):485. PubMed ID: 39390438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
    Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
    Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.
    Chang EES; Ho PW; Liu HF; Pang SY; Leung CT; Malki Y; Choi ZY; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Feb; 11(1):10. PubMed ID: 35152914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
    Estanga A; Rodriguez-Oroz MC; Ruiz-Martinez J; Barandiaran M; Gorostidi A; Bergareche A; Mondragon E; Lopez de Munain A; Marti-Masso JF
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1097-100. PubMed ID: 25127457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.